Trident Lifeline

Trident Lifeline Quick Ratio

Delisted·Sep 16, 2026

The Quick Ratio (Acid Test) of Trident Lifeline (543616.BO) as of Nov 4, 2026 is 1.16. In the previous year, Quick Ratio (Acid Test) was 1.94 — a change of -40.34% (lower).

Quick Ratio

1.16

YoY

-40.34%

Last updated:

Quick Ratio (Acid Test) of Trident Lifeline is 2025 1.16 . Quick Ratio (Acid Test) of Trident Lifeline was 2024 1.94 . It decreases by -40.34% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trident Lifeline Stock analysis

What does Trident Lifeline do? Trident Lifeline Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across seven geographical segments including India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, and Rest of World. The company produces a diverse range of pharmaceutical formulations such as capsules, tablets, liquid ointments, gels, mouthwashes, and toothpaste under contract manufacturing on loan license. Its product portfolio features drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive, Anti Lipidemic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Non-Steroidal Anti-Inflammatory Drug (NSAIDS). The primary buyers are healthcare providers and consumers in the pharmaceutical market, with a focus on both domestic and international markets. The company's revenue streams are derived from the sale of its extensive product range, which includes both prescription and over-the-counter medications. By operating through multiple geographical segments, Trident Lifeline Ltd. caters to a broad customer base across different regions, ensuring consistent demand for its pharmaceutical formulations. The contract manufacturing model under loan license allows the company to leverage partnerships without significant capital investment, optimizing production costs and scalability. Trident Lifeline Ltd. targets healthcare providers and consumers seeking affordable pharmaceutical solutions, particularly in emerging markets. Its product offerings address a wide spectrum of health needs, from common ailments like diarrhea and fungal infections to chronic conditions such as diabetes and hypertension. This strategic focus on diverse drug categories ensures steady demand across its operational segments, supporting sustainable revenue growth. Trident Lifeline is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trident Lifeline stock

Quick Ratio (Acid Test) of Trident Lifeline is 1.16 in 2025.

Quick Ratio (Acid Test) of Trident Lifeline changed from 1.94 to 1.16, representing a -40.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Trident Lifeline since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Trident Lifeline with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Trident Lifeline

All Key Metrics — Trident Lifeline